<SEC-DOCUMENT>0001104659-25-047011-index.html : 20250512
<SEC-HEADER>0001104659-25-047011.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512071230
ACCESSION NUMBER:		0001104659-25-047011
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		30
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-285035
		FILM NUMBER:		25932569

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>tm256615-13_s4a.htm
<DESCRIPTION>S-4/A
<TEXT>
Document 1 - file: tm256615-13_s4a.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm256615d15_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
Document 2 - file: tm256615d15_ex5-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>tm256615d15_ex8-1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
Document 3 - file: tm256615d15_ex8-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>tm256615d15_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
Document 4 - file: tm256615d15_ex23-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>tm256615d15_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
Document 5 - file: tm256615d15_ex23-2.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>6
<FILENAME>tm256615d15_ex23-4.htm
<DESCRIPTION>EXHIBIT 23.4
<TEXT>
Document 6 - file: tm256615d15_ex23-4.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>tm256615d15_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
Document 7 - file: tm256615d15_ex-filingfees.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>bc_inhibitors-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 8 - file: bc_inhibitors-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>bc_paidvsnetincome-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 9 - file: bc_paidvsnetincome-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>bc_paidvstsr-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 10 - file: bc_paidvstsr-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>fc_chemotherapy-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 11 - file: fc_chemotherapy-4clr.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>fc_cr002adc-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 12 - file: fc_cr002adc-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ft_lucidcapnewyork-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 13 - file: ft_lucidcapnewyork-bw.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>lc_cooperative-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 14 - file: lc_cooperative-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>lc_nsclc-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 15 - file: lc_nsclc-4clr.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>lg_crescent-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 16 - file: lg_crescent-4clr.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>lg_glycomimetics-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 17 - file: lg_glycomimetics-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>lg_lucidcapital-bwlr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 18 - file: lg_lucidcapital-bwlr.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>lg_walkers-bwlr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 19 - file: lg_walkers-bwlr.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ph_antivegf-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 20 - file: ph_antivegf-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ph_cr001-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 21 - file: ph_cr001-4clr.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ph_vegf-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 22 - file: ph_vegf-4clr.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>px_glycoproxy1pg01-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 23 - file: px_glycoproxy1pg01-bw.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>px_glycoproxy1pg02-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 24 - file: px_glycoproxy1pg02-bw.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>sg_lucidcapitalmarkets-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 25 - file: sg_lucidcapitalmarkets-bw.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tb_clinicaldevelop-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 26 - file: tb_clinicaldevelop-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tb_pfs-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 27 - file: tb_pfs-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tm256615d15_ex8-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 28 - file: tm256615d15_ex8-1img01.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tm256615d15_ex23-4img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 29 - file: tm256615d15_ex23-4img001.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tm256615d15_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 30 - file: tm256615d15_ex5-1img001.jpg

</DOCUMENT>
</SEC-DOCUMENT>